Cargando…
MYD88 in the driver’s seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications
More than 50 subtypes of B-cell non-Hodgkin lymphoma (B-NHL) are recognized in the most recent World Health Organization classification of 2016. The current treatment paradigm, however, is largely based on ‘one-size-fits-all’ immune-chemotherapy. Unfortunately, this therapeutic strategy is inadequat...
Autores principales: | de Groen, Ruben A.L., Schrader, Anne M.R., Kersten, Marie José, Pals, Steven T., Vermaat, Joost S.P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959184/ https://www.ncbi.nlm.nih.gov/pubmed/31699794 http://dx.doi.org/10.3324/haematol.2019.227272 |
Ejemplares similares
-
MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis
por: Vermaat, Joost S., et al.
Publicado: (2020) -
The driver's seat /
por: Spark, Muriel
Publicado: (1974) -
The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain
por: Minderman, Marthe, et al.
Publicado: (2023) -
Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations
por: Kersten, M J, et al.
Publicado: (2014) -
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
por: Munshi, Manit, et al.
Publicado: (2020)